"Aurobindo Pharma Slips 2% Despite Strong Revenue Growth, Profit Margins Under Pressure"

Aurobindo Pharma Drops 2% Amid Mixed Financial Performance Aurobindo Pharma shares fell 2.01% to Rs 1,141.50 in today’s trade, ranking among the top losers in the NIFTY MIDCAP 150 index. Despite a strong rise in revenue, the company reported a dip in quarterly net profit and EPS. For Q3 FY25, revenue rose to Rs 7,978.52 Cr (vs. Rs 7,351.78 Cr YoY), while net profit declined to Rs 843.98 Cr from Rs 942.56 Cr. Annual performance remained solid, with FY24 revenue at Rs 29,001.87 Cr and net profit at Rs 3,186.13 Cr. Key financials show a book value of Rs 509.49/share, ROE of 10.63%, and a debt-to-equity ratio of 0.21. Despite a previously bullish sentiment, today’s decline signals shifting investor outlook.